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Neurotensin-receptor-1 (NTSR1) is regularly overexpressed in various cancers
and contributes to the proliferation, survival, migration, invasion, and angiogenesis of tumors.
NTSR1-targeting vectors have demonstrated promise in both diagnostic and therapeutic aspects.
Unfortunately, the relatively poor in vivo metabolic stability and high renal uptake and retention
of NTSR1-targeted compounds have hampered the translation to the clinic. In this research, we
utilized a one-bead one-compound (OBOC) peptide library approach to make targeted
modifications at the naturally charged residues of an NTS (4-13) sequence to discover an NTS
derivative with comparable affinity to NTSR1, acceptable in vivo stability, and tolerable renal
retention. Subsequent in vitro screening and analysis by LC-MS/MS and PEAKS® Studio
software determined the modifications of interest for further investigation with the most favorable
observed binding affinity toward NTSR1 were Gln at Glu4, Lys(Me2) at Lys6, and Arg(NO2) at
Arg9.
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1.1 Combinatorial Chemistry and Drug Discovery
Combinatorial chemistry involves the generation of a large array of structurally diverse
compounds through systematic linkage [1]. These compound libraries can be concurrently
screened for interactions with biological targets of interest [1]. Positive hits can then be identified
and analyzed. The first described use of combinatorial chemistry for the rapid concurrent
synthesis of hundreds of compounds dates to a 1984 experiment by Geysen, Meloen, and
Barteling in which a synthetic method utilizing polyethylene rods (pins) was employed to create a
library of overlapping hexapeptide antigens of foot-and-mouth disease virus type O1 [1,2]. About
a year later Houghten furthered the concept of combinatorial chemistry through the development
of a technique utilizing solvent-permeable bags to synthesize hundreds of hemagglutinin HA1
analogs [3].
In parallel to the research of Houghten in 1985, Smith described a method utilizing
foreign DNA fragments and M13 phages to generate novel expression vectors displayed on the
virion surface [4]. The method described by Smith was quickly optimized through the addition of
an isolation, amplification, and re-panning (biopanning) process to become known as the first
biological (diversity generated biologically) peptide library method. The phage-display peptide
library method would give rise to other early biological library methods such as yeast-display and
polysome-display peptide libraries [1]. The development of chemical (diversity generated
chemically) combinatorial libraries was furthered by the one-bead one-compound (OBOC)
method described by Lam et al. [5] and a solution-phase synthesis method described by Houghten
et al. [6] in 1991 with the first small-molecule combinatorial library being reported by Bunin and
Ellman in 1992 [7].
Since the mid-80s and the early 90s, advancements in the area of combinatorial libraries
have continued to be made. mRNA-display peptide libraries utilizing unnatural and D-amino
acids were described by Frankel et al. [8], Josephson et al. [9], and Murakami et al. [10] in the
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mid-2000s, as well as methods of post-translation modifications of phage-display libraries
described by Heinis et al. in 2009 [11], gave rise to DNA-encoded chemical libraries (DECLs).
The conformational constraint and potential for greater chemical diversity generated by DECLs
makes this method potentially more useful for the development of drugs and is currently a major
focus of the field.
Combinatorial chemistry is useful for both drug lead discovery and optimization [12].
Many combinatorial methods can generate vast, diverse libraries of hundreds to millions of
compounds with relative ease. These compounds can be rapidly and concurrently screened by
high throughput methods in conjunction with computational methods for drug lead discovery as
well as screened by lower throughput, specific methods for lead optimization.

1.2 One-Bead One-Compound Peptide Libraries
Each combinatorial library method has pros and cons. The choice of a method is relative
to the goal of the research. OBOC libraries are of interest to this research. The diversity of OBOC
libraries is generated chemically through a split-mix method (Figure 1.1) of synthesis on a solidsupport resin [13]. Unlike many biological libraries, OBOC libraries can incorporate unnatural
and D-amino acids in addition to L-amino acids and post-translational modifications such as
glycosylation and phosphorylation [14-16]. OBOC libraries are relatively inexpensive, easy to
create, and easy to screen through on-bead processes in vitro or ex vivo. OBOC libraries,
however, cannot be used to select specifically for peptides that internalize into cells in vitro or for
in vivo selection due to the large size of the beads [13]. Peptide sequences of identified positive
hits can be determined by Edman sequencing or MS/MS [13]. OBOC libraries are spatially
separable, allowing for the incorporation of multiple different motifs on a single bead [17]. The
high efficiency of synthesis and screening and overall design of OBOC libraries makes them ideal
for use in the optimization of known ligands [13].
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As normal solid-phase peptide synthesis methodology grows peptides from the Cterminus to the N-terminus, proteins and enzymes which recognize the C-terminus of another
peptide or protein are challenging targets for peptide library screening. Although some
ribosomally synthesized biological peptide libraries have been generated with free C-termini, the
peptide sequences were generally very small (<20 amino acids) and of low yield [18-22]. A
method described by Joo and Pei in 2008 [23] utilizing a large inverted OBOC library to screen
against C-termini targets is of appeal in the selection of OBOC library methodologies for
research. This method allows for well-established, high-yield, solid-phase peptide synthesis
starting from the C-terminus to the free amine of a solid support. A linker consisting of
fluorenylmethyloxycarbonyl-L-glutamic acid 1-allyl ester (Fmoc-Glu-OAll) and 4(hydroxymethyl)benzoic acid (HMBA) is added preceding the binding sequence (Figure 1.2a).
The first amino acid of the binding sequence (free C-termini) is coupled to the free hydroxyl
group of HMBA via Steglich esterification (Figure 1.2b). Subsequent amino acids and any
terminal linkers are added to the peptide using standard Fmoc chemistry (Figure 1.2c). With the
completion of the peptide, the allyl group is deprotected from the glutamic acid linker and
cyclized with the deprotected N-terminus of the peptide (Figure 1.2d-f). The ester bond formed
between HMBA and the first amino acid of the sequence is hydrolyzed yielding the inverted, Cterminial-directed sequence (Figure 1.2g) [23]. A whole-bead synthesis approach can be utilized
for analysis via mass spectrometry or a biphasic tag can be incorporated as an N-termini free
‘template’ sequence for analysis via Edman sequencing [14].

5

Figure 1.1. Example of split-mix OBOC peptide library synthesis using leucine (L), alanine (A),
and threonine (T). The resin is split; L, A, and T are coupled individually yielding all
possible combinations (n=3). The resin is mixed and split again; L, A, and T are
coupled individually yielding all possible combinations (n=9). The resin is mixed and
split again; L, A, and T are coupled individually yielding all possible combinations
(n=27).
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Figure 1.2. General inversion schematic. (a) Fmoc synthesis of primary linker including GluOAll and HMBA. (b) Steglich esterification of first binding sequence amino acid (ex.
Leu). (c) Standard Fmoc synthesis of binding sequence. (d) Fmoc deprotection of
terminal binding sequence amino acid. (e) Allyl deprotection of Glu. (f) Cyclization.
(g) Inversion.
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1.3 Neurotensin and Cancer
Neurotensin (NTS) is a 13 amino acid, linear neuropeptide (Figure 1.3a) discovered and
isolated from the bovine hypothalamus by Carraway and Leeman in 1973 that is implicated in the
regulation of luteinizing hormone and prolactin release as well as significant interactions with the
dopaminergic system [24]. NTS is found in both the central nervous system and peripheral tissues
(specifically the intestinal mucosa) [25-27]. NTS is the natural ligand for NTS-class of receptors.
To date, four NTS receptors have been identified; neurotensin-receptor-1 (NTSR1), 2 (NTSR2), 3
(NTSR3), and 4 (NTSR4) [28]. NTSR1, NTSR2, and NTSR4 are members of the G-protein
coupled receptor family whereas NTSR3 is a member of the sortilin protein family [28-32]. NTS
receptors, particularly NTSRs 1-3, are regularly overexpressed in various cancers (Table 1.1) and
contribute to the proliferation, survival, migration, invasion, and angiogenesis of tumors [28,34].
The degree and incidence of NTS receptor overexpression in such an extensive list of
cancers has led to increased interest in the development of NTS-based therapeutics and
diagnostics, – particularly radiopharmaceutical imaging. Despite the interest and promise of NTSbased pharmaceuticals, very few clinical studies have been performed. Studies performed by
Buchegger et al. in 2003 and Gabriel et al. in 2011 both utilizing technetium-99m radiolabeled
NTS analogs to target NTS receptors concluded the suboptimal pharmacokinetic properties such
as low metabolic stability and high renal retention of the compounds must be improved to warrant
further trials [45,46].

8

Figure 1.3. NTS peptide and analog structures. (a) NTS peptide sequence 1-13 (pGlu1-Leu2-Tyr3Glu4-Asn5-Lys6-Pro7-Arg8-Arg9-Pro10-Tyr11-Ile12-Leu13). Binding sequence 8-13 in
red (Arg8-Arg9-Pro10-Tyr11-Ile12-Leu13). (b) Modified binding sequence for research
NTS (4-13) (Glu4-Asn5-Lys6-Pro7-Arg8-Arg9-Pro10-Tyr11-Ile12-Leu13) (c) Modified
NTS (4-13) sequence including Dmt 11 and Tle12 (Green) and denoting residues
targeted for substitution (Blue): Glu 4, Lys6, Arg8, & Arg9.
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Table 1.1. Neurotensin Receptor Overexpression by Cancer Type
Cancer Type

% Overexpression

Reference

Astrocytoma

43

[35]

Colon Adenocarcinoma

76/24 (Strong/Moderate)

[35]

Ductal Pancreatic

75

[37, 38]

Ewing’s Sarcoma

65

[35]

Head and Neck Squamous

++++

[39]

91

[40,41]

Malignant Mesothelioma

90

[42]

Medullary Thyroid

29

[35]

Medulloblastoma

38

[35]

Meningioma

52

[35]

Non-Small Cell Lung

60

[43]

Small-Cell Lung Cancer

25

[35]

Prostate Cancer

+++++

[44]

Adenocarcinoma

Cell Carcinoma
Invasive Ductal Breast
Cancers

Carcinoma

Cancer

+

Significant overexpression of NTSR1

++

Significant overexpression of NTSR1-3
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1.4 Neurotensin Receptor 1
NTSR1 is a 418-amino-acid protein in humans (424-amino-acid protein in rats) which
mediates most of the NTS-related biological effects and is of interest in relation to cancer
imaging and therapy [29,47,48]. The relative overexpression of NTSR1 in many prevalent
cancers and the minimal or lack of NTSR1 expression in non-cancerous surrounding tissues in
conjunction with the high reported affinity of NTS to NTSR1 (Kd = ~0.2 nM) makes NTSR1 a
promising potential target for NTS-based therapeutic and imaging agents [49,50].
Binding interactions of NTSR1 were first described by Labbé-Jullié et al. in 1998
utilizing a receptor-mutagenesis alanine-scanning method to screen for critical residues of a
nonpeptide NTS antagonist [51]. Some information regarding the structural basis for selectivity
was gained but much was still unknown. About a decade later, White et al. were able to obtain
the crystal structure of NTS (8-13) bound to Rattus norvegicus NTSR1 (NTSR1-GW5-T4L) at a
resolution of 2.8 Å (Figure 1.4) [30]. Detailed analysis of the receptor-ligand complex found the
NTSR1 binding pocket was composed of three extracellular loops and six transmembrane helices
(TM1-6). Charge interactions were observed between positive-charged arginine sidechains of
NTS (8-13) (Arg8 & Arg9) with the electronegative rim of the binding site. Data suggests the
likely formation of a salt bridge between the C-terminus of NTS (8-13) and R327 of the receptor
in addition to extensive van der Waals interactions and hydrogen bonding directs the N-terminus
out from the binding pocket (Figure 1.5). This information gained from the ligand-receptor
crystal structure of NTSR1 confirms previous studies indicating only a truncated NTS (8-13)
sequence is necessary to elicit a high binding affinity toward NTSR1 [51-55].
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Figure 1.4. NTSR1 structure bound to peptide agonist NTS (8-13). (a) Side view. (b)
Extracellular view. (c) Intracellular view. Adapted with permission from Nature
Publishing Group [30]
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Figure 1.5. NTSR1 binding pocket. Extracellular view, NTS (8-13) bound. (a) Ligand-binding
pocket. (b) Key NTSR1 residues (green residues with grey labels) and key NTS (813) residues (grey residues with black labels). (c) Charge complementarity between
NTS (8-13) and its binding pocket (red, negative; blue, positive). Adapted with
permission from Nature Publishing Group [30].
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1.5 Project Overview
NTSR1 is regularly overexpressed in various cancers and contributes to the proliferation,
survival, migration, invasion, and angiogenesis of tumors [28,34]. NTSR1-targeting vectors have
demonstrated promise in both diagnostic and therapeutic aspects. Unfortunately, the relatively
poor in vivo metabolic stability and high renal uptake and retention of NTSR1-targeted
compounds have hampered the translation to the clinic [90]. To address the metabolic stability
issue, unnatural amino acids are regularly incorporated into peptide-conjugates to great effect
[73-78]. Renal uptake and retention issues are regularly observed in these compounds as a result
of increasing molecular (positive) charge interactions with negative brush border of the proximal
tubules and receptor-mediated endocytosis by megalin and cubilin receptors [85]. This issue has
been addressed to some effect by reducing the overall charge of these peptides through the
inclusion of modified amino acid residues [86,87]. The purpose of this research is to discover
new NTS derivatives with comparable binding affinity to established NTSR1-targeting agents
with acceptable in vivo stability and tolerable renal retention. This will be achieved through the
synthesis and screening of an OBOC peptide library with charge-based substitutions at Arg9 (X1),
Arg8 (X2), Lys6 (X3), and Glu4 (X4) in a modified NTS (4-13) sequence (Figure 1.3b & c). The
experimental residues chosen for substitution were commercially available compounds designed
to closely reflect the native NTS sequence. This afforded the best chance at discovering an
NTSR1 targeting vector with comparable affinity to NTSR1. Additionally, these residues were
selected to potentially increase in vivo stability through the inclusion of unnatural amino acids
and to potentially reduce renal uptake and retention through the reduction of overall peptide
charge.
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2.1 Materials
Fluorenylmethyloxycarbonyl-glutamic acid 1-allyl ester (Fmoc-Glu-OAll), 4(Hydroxymethyl)benzoic acid (HMBA), Fmoc-tert-leucine-OH (Fmoc-Tle-OH), 1[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide
hexafluorophosphate (HATU),N,N-diisopropylethylamine (DIEA), N-N-diethylamine (DEA),
tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4), Nα-Fmoc-Nδ-Boc-ornithine-OH (FmocOrn(Boc)-OH), Fmoc-citrulline-OH (Fmoc-Cit-OH), Fmoc- Nω-methyl-arginine(Pbf)-OH (FmocArg(Me,Pbf)-OH), Fmoc- Nω-nitro-arginine-OH (Fmoc-Arg(NO2)-OH), Fmoc-Nε-azido-lysineOH (Fmoc-Lys(N3)-OH), Fmoc-Met-OSu, and Boc-Phe-OSu were obtained from Chem-Impex
International (Wood Dale, IL). Thioanisole, 2,2’-(ethylenedioxy)diethanethiol (DODT),
triisopropylsilane (TIS), phenol, cyanogen bromide (CNBr), bromophenol blue, N-N’diisopropylcarbodiimide (DIC), and 4-dimethylaminopyridine (DMAP) were obtained from
Sigma-Aldrich (St. Louis, MO). N,N-dimethylformamide (DMF), dichloromethane (DCM),
formic acid (FA), tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP), sodium hydroxide
(NaOH), acetonitrile (ACN), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES),
hydrochloric acid, acetic anhydride, diethyl ether, and fetal bovine serum (FBS) were obtained
from Fisher Scientific (Fair Lawn, NJ). Benzotriazol-1-ol (HOBt) and 3-Hydroxytriazolo[4,5b]pyridine (HOAt) were obtained from Advanced ChemTech (Louisville, KY).
Triphenylphosphine (TPP), trifluoroacetic acid (TFA), and glycine HCl were obtained from Alfa
Aesar (Ward Hill, MA). Fmoc-Nε-methyl-Nε-boc-lysine-OH (Fmoc-Lys(Me,Boc)-OH), Fmoc-Nεdimethyl-lysine-OH (Fmoc-Lys(Me2)-OH), and Fmoc-Nε-trimethylamonium-lysine-OH (FmocLys(Me3)-OH) were obtained from BioSystems (Shelbyville, KY). Standard Fmoc-protected
amino acids, Boc-glycine-OH, (Boc-Gly-OH) and Fmoc-ß-alanine-OH (Fmoc-ß-Ala-OH) were
obtained from NovaBiochem (Hohenbrunn, Germany).
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(Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) was obtained
from Oakwood Chemical (Estill, SC). Fmoc-2,6-dimethyl tyrosine-OH (Fmoc-Dmt-OH) was
obtained from Key Organics (Camelford, United Kingdom). Sodium dimethyldithiocarbamate
(NaDMDTC) was obtained from Tokyo Chemical Industry (Portland, OR). Piperidine was
obtained from EMD Millpore (Billerica, MA). TentaGel® S-NH2 (0.25 mmol/g loading) was
obtained from Rapp Polymere (Tuebingen, Germany). Poly-Prep® chromatography columns (12
mL) were obtained from Bio-Rad (Hercules, CA). HT-29 (NCI-PBCF-HTB38) human colon
adenocarcinoma cells were obtained from American Type Culture Collection (Manassas, VA).
TrypLE™ Express and amphotericin B (250 µg/mL) were obtained from Innvitrogen (Grand
Island, NY). Phosphate buffered saline (PBS 1x) and L-glutamine were obtained from Mediatech,
Inc (Manassas, VA). Plasmocin™ was obtained from InvivoGen (San Diego, CA). McCoy’s 5A
medium (1.5 mM L-glutamine, 2.2 g/L sodium bicarbonate) was obtained from GE Life Sciences
(Marlborough, MA).

2.2 Synthesis of Peptide Libraries
For this project, we synthesized two peptide libraries. The first peptide library was a
biphasic, surface-area-reduced library (Low-Surface-Density Peptide Library). The second
peptide library was a high-surface-density, non-surface-area-reduced library (High-SurfaceDensity Peptide Library). In order to reduce unnecessary repetition common methodologies are
described for the assembly of both peptide libraries when possible. Protocols that are specific for
a particular peptide library are included under the methods associated with that library.
2.2.1 Low-Surface-Density Peptide Library
The Low-Surface-Density Peptide Library was manually synthesized and included a
surface-area-reduction step to address potential nonspecific binding during the screening process.
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A biphasic, N-terminus-directed tag was also included in our Low-Surface-Density Peptide
Library to facilitate analysis by PED-MALDI.
2.2.1.1 Surface Area Reduction
About 1g of TentaGel® S-NH2 (0.25 mmol loading) resin was weighed out into a 12 mL
Poly-Prep® chromatography column and swollen overnight in water (Figure 2.1a). The resin was
filtered and quickly resuspended in 5 mL of 55/45 (v/v) DCM/diethyl ether containing 0.10 equiv.
Fmoc-Met-OSu, 0.40 equiv. Boc-Phe-OSu, and 0.5 equiv. DIEA and was mixed for 20 minutes
on a pulsing vortex to selectively couple surface amines in a biphasic system (Figure 2.1b).
Equivalents were calculated relative to resin loading capacity (1 equiv. = 0.25 mmol/g of resin).
The completeness of this coupling was determined using the bromophenol blue test (Figure 2.2a).
The resin was washed sequentially with 15 mL of a 55/45 DCM/diethyl ether solution and 40 mL
of DMF before being treated with 4 equiv. Fmoc-Met-OH, 4 equiv. HATU, 4 equiv. HOAt, and
10 equiv. DIEA dissolved in 5 mL NMP and mixed for 90 minutes on a pulsing vortex to
conjugate Met to the remainder of the resin (Figure 2.1c). The resin was treated with 5 mL of a
50% (v/v) TFA/DCM solution for 30 minutes on a pulsing vortex to remove the Boc group from
Phe. The resin was filtered using the Poly-Prep® column and washed sequentially with 25 mL of
DMF, 25 mL of DCM, and 5 mL of a 5% (v/v) DIEA/DCM solution (Figure 2.1d). Excess acetic
anhydride (20 equiv.) and DIEA (20 equiv.) in 5 mL of DMF was added to the resin to cap the Nterminus of Phe and prevent further coupling of ~80% of the exterior of the resin (Figure 2.1e).
The resin was dried for 1 minute under vacuum and stored at -20 °C overnight.
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Figure 2.1. Surface area reduction schematic. (a) Resin swollen overnight in water. (b) 0.4 equiv.
Boc-Phe-OSu, 0.1 equiv. Fmoc-Met-OSu, 0.5 equiv. DIEA in 55/45 (v/v)
DCM/diethyl ether for 30 mins. (c) Conjugation of Fmoc-Met-OH to interior. (d) Boc
deprotection of Phe. (e) N-terminus capping of Phe with excess acetic anhydride. (f)
General synthesis of peptide to complete, 80% surface-area-reduced ‘binding’
sequence with high-surface-density inner ‘coding’ tag for PED-MALDI analysis.
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Figure 2.2. Bromophenol blue test for primary and secondary amines. Five drops of 0.05% (w/v)
bromophenol blue dissolved in DMF. (a) Biphasic coupling; negative for free amine
on outer portion of bead (coupled, colorless), positive for free amine on inner portion
of bead (uncoupled, blue). (b) Positive resin for free amine (uncoupled, blue). (c)
Negative resin for free amine (coupled, colorless). 100x magnification under a brightfield microscope.
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2.2.1.2 General Amino Acid Coupling Protocol
Standard Fmoc-HATU chemistry was performed using 4 equiv. amino acid, 4 equiv.
HATU, 4 equiv. HOAt, and 10 equiv. DIEA dissolved in 5 mL NMP unless otherwise noted.
Coupling reactions were mixed for 90 minutes on a pulsing vortex and were washed with 25 mL
of DMF and 25 mL of DCM after each step unless otherwise noted. Fmoc deprotections were
carried out using 20% (v/v) piperidine in NMP. To the resin was added 5 mL of the deprotection
solution followed by mixing for 15 minutes on a pulsing vortex. The resultant deprotection
solution was filtered using the Poly-Prep® column and the resin was washed with 50 mL of DMF
and 25 mL of DCM. The completeness of each coupling and deprotection step was determined by
adding 5 drops of a 0.05% (w/v) bromophenol blue solution in DMF unless otherwise noted
(Figure 2.2a-c).
2.2.1.3 Synthesis of Primary Linker
The resin was reswollen for 15 minutes in 10 mL of DMF. Using the basic amino acid
coupling protocol described in section 2.2.1.2, Leu, Leu, ß-Ala, and ß-Ala were conjugated to the
resin (Figure 2.3a). Following the deprotection of the terminal ß-Ala, the resin was swollen
overnight in 5 mL of water (Figure 2.3b). The resin was filtered using the Poly-Prep® column
and quickly resuspended in 5 mL of 55/45 (v/v) DCM/diethyl ether containing 0.33 equiv. FmocGlu-OAll (proportionate to % of amines exposed on exterior of bead), 1.32 equiv. HATU, 1.32
equiv. HOAt, and 3.3 equiv. DIEA and was mixed for 30 minutes on a pulsing vortex to
selectively couple surface amines in the biphasic system. The resin was washed with 15 mL of a
55/45 DCM/diethyl ether solution and 40 mL of DMF before Boc-Gly was conjugated to the
interior linker (Figure 2.3c). The Fmoc group was removed from Glu-OAll and HMBA was
conjugated to the exterior linker (Figure 2.3d & e). 5 mL of TFA was added to the resin and
mixed for 60 minutes on a pulsing vortex to remove Boc from Gly. The deprotection solution was
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filtered using the Poly-Prep® column and the resin was washed with 50 mL of DMF and 25 mL
of DCM (Figure 2.3f) before Ala was conjugated to the interior linker (Figure 2.3g).
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Figure 2.3. Low-Surface-Density Peptide Library synthesis schematic. (a) Standard Fmoc/HATU
chemistry synthesis of primary linker. (b) Swell in water overnight then Fmoc-GluOAll addition to exterior in 55/45 (v/v) DCM/diethyl ether. (c) Conjugation of BocGly spacer to interior. (d) Fmoc deprotection of Glu-OAll. (e) Conjugation of HMBA
to exterior. (f) Boc deprotection of Gly. (g) Conjugation of Ala spacer to interior. (h)
Fmoc deprotection of Ala. (i) Conjugation of Leu13 to interior. (j) Steglich
esterification conjugation of Leu 13 to exterior. (k) Whole-bead Fmoc deprotection of
Leu13. (l) Standard Fmoc/HATU chemistry synthesis of experimental region and
terminal linker (Split-mix addition of experimental substitutions at X1, X2, X3, and
X4). (m) Allyl deprotection. (n) Fmoc deprotection of terminal Ala. (o) PyBOP/HOBt
cyclization. (p) Ester hydrolysis. (q) Sidechain deprotection. (X4 = Glu substitutions,
X3 Lys substitutions, X2 & X1 = Arg substitutions, B = ßAla)
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2.2.1.4 Addition of First Amino Acid (Leu13)
Using general methods previously described in section 2.2.1.2, the Fmoc protecting
group was removed from the Ala located in the interior of the bead. Subsequently, Leu13 was
conjugated to the interior amine using standard HATU chemistry (Figure 2.3i). Leu13 was then
conjugated to the alcohol of the HMBA on the exterior of the bead by Steglich esterification. A
solution consisting of 3 equiv. of Fmoc-Leu-OH, 3 equiv. of DIC, and 0.1 equiv. of DMAP in 5
mL of DCM was mixed on a pulsing vortex for 5 minutes. The activated solution was added to
the resin and allowed to react overnight at room temperature on an orbital shaker at 60 RPM and
washed sequentially with 25 mL of DCM, 25 mL of DMF, and 25 mL of DCM (Figure 2.3j).
2.2.2 High-Surface-Density Peptide Library
The second library was synthesized on an automated Liberty microwave peptide
synthesizer (Model 908505) from CEM (Matthews, NC) using 500 mg of TentaGel® S-NH2
(0.25 mmol loading) resin and did not include a surface-area-reduction step. Our High-SurfaceDensity Peptide Library also did not include a biphasic coding tag as we intended to identify the
peptides by de novo peptide sequencing using MS/MS analysis.
2.2.2.1 General Amino Acid Coupling Protocol
Standard Fmoc-HATU chemistry utilizing a 0.05 mmol synthesis scale was performed on
500 mg of TentaGel® S-NH2 (0.25 mmol loading) resin unless otherwise noted. 5 equiv. (250
µmol) of each natural and unnatural amino acid per coupling step in 1.3 mL of DMF were
activated with 5 equiv. of HATU/HOAt (250 µmol each) in 1 mL of DMF and 0.5 mL DIEA in
NMP (1:2 v/v) and added to the resin. Equivalents were calculated relative to resin loading
capacity (1 equiv. = 0.25 mmol/g of resin). Each coupling step performed with the peptide
synthesizer was subjected to microwave heating (25 W) up to 80 °C over 5 minutes and was
carried out twice to ensure complete coupling. Fmoc deprotections were carried out by adding 5
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mL of a 20% piperidine solution in DMF to the reaction vessel and heating to 45 °C over 30
seconds before the deprotection solution was filtered and 5 mL of a fresh 20% piperidine solution
was added to the reaction vessel and heated to 80 °C for 3 minutes. The Fmoc deprotection step
was UV monitored to gauge the completeness of the preceding coupling unless otherwise noted.
The resin was thoroughly washed with 20 mL of DMF after each step.
2.2.2.2 Synthesis of Primary Linker and Addition of First Amino Acid (Leu13)
Utilizing the protocols outlines in section 2.2.2.1, Met, Leu, Leu, ß-Ala, ß-Ala, Glu-OAll,
and HMBA were sequentially conjugated to the resin (Figure 2.4a). Next, Leu13 was conjugated
to the primary alcohol of the HMBA by Steglich esterification. The resin was transferred to a 12
mL Poly-Prep® chromatography column and washed with 25 mL of DMF and 25 mL of DCM.
Separately, 3 equiv. (150 µmol) of Fmoc-Leu-OH, 3 equiv. (150 µmol) of DIC, and 0.1 equiv. (5
µmol) of DMAP in 5 mL of DCM were mixed on a pulsing vortex for 5 minutes. The activated
solution was added to the resin and allowed to couple overnight at room temperature on an orbital
shaker at 60 RPM. The resin was washed sequentially with 25 mL of DCM, 25 mL of DMF, and
25 mL of DCM (Figure 2.4b).
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Figure 2.4. High-Surface-Density Peptide Library synthesis schematic. (a) Standard
Fmoc/HATU chemistry synthesis of primary linker. (b) Steglich esterification
addition of Leu13. (c) Fmoc deprotection of Leu 13. (d) Standard Fmoc/HATU
chemistry synthesis of experimental region and terminal linker (Split-mix addition of
experimental substitutions at X1, X2, X3, & X4). (e) Allyl deprotection. (f) Fmoc
deprotection of terminal Ala. (g) PyBOP/HOBt cyclization. (h) Ester hydrolysis. (i)
Sidechain deprotection. (X4 = Glu substitutions, X3 Lys substitutions, X2 & X1 = Arg
substitutions, B = ßAla.
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2.3 Split-Mix Synthesis of Tle12-Glu4 and Terminal Linker
The synthesis of Tle12 through to the terminal linker was similar for both libraries.
Synthesis steps were performed manually for the Low-Surface-Density Library with amounts
detailed in section 2.2.1.2 whereas synthesis steps were performed by the automated peptide
synthesizer for the High-Surface-Density Library with amounts detailed in section 2.2.2.1. The
resin was manually pooled and mixed after every split synthesis step.
Using the appropriate methodologies, Fmoc was removed from Leu13 (Figure 2.3k &
Figure 2.4c) and Tle12, Dmt11, and Pro10 were subsequently conjugated to the resin. The resin was
split by volume into six equal portions (6 mL total; 1 mL = ~167 or ~83 mg resin per) in
preparation for coupling at the first random position (X 1 or Arg9). Each portion was individually
coupled with one of six native or experimental amino acids as illustrated in Figure 2.5. The Fmoc
group was removed from the Arg9/X1 substitution. The resin was again split by volume into six
equal portions and couplings at the second random position (X 2 or Arg8) were performed as
detailed above. Using standard procedures, Pro7 was conjugated to the growing peptide.
Following this, the resin was split by volume into eight equal portions (8 mL total; 1 mL = ~125
or ~62 mg resin per) in preparation for coupling at the third random position (X3 or Lys6). Each
portion was individually coupled with one of eight native or experimental amino acids as
illustrated in Figure 2.6. Employing appropriate methodologies, Asn5 was conjugated to the resin.
Lastly, the resin was split by volume into three equal portions (3 mL total; 1 mL = ~333 or ~167
mg resin per) in preparation for coupling at the fourth and final random position (X 4 or Glu4).
Each portion was individually coupled with one of three native or experimental amino acids as
illustrated in Figure 2.7. A terminal linker consisting of two Ala residues was conjugated to the
resin (Figure 2.3l & Figure 2.4d) with the terminal Ala Fmoc protected.
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Figure 2.5. Deprotected Arg substitutions at residues 8 & 9 (X2 & X1). (a) Arg. (b) Arg(Me). (c)
Arg(NO2). (d) Cit. (e) Gln. (f) Asp. Binding sequence substitution example shown
above.
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Figure 2.6. Deprotected Lys substitutions at residue 6 (X3). (a) Lys. (b) Lys(Me). (c) Lys(Me2).
(d) Lys(Me3). (e) Lys(N3). (f) Orn. (g) Gln. (h) Asp. Binding sequence substitution
example shown above.
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Figure 2.7. Deprotected Glu substitutions at residue 4 (X4). (a) Glu. (b) Gln. (c) Asp. Binding
sequence substitution example shown above.
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2.4 Cyclization, Inversion, and Final Deprotection
The cyclization, inversion, and final deprotection steps were consistent across both the
Low-Surface-Density Peptide Library and the High-Surface-Density Peptide Library.
2.4.1 Cyclization of the Assembled Peptide on the Resin
In order to cyclize the peptides, the allyl protecting group was removed as follows. To a 5
mL light-sensitive glass reaction vessel was added 250 mg of resin. Concurrently, 0.05 equiv.
(2.5 µmol) of Pd(PPh3)4 and 0.10 equiv. (5 µmol) of TPP were dissolved in 5 mL of anhydrous
THF. 100 µL of a 1 M solution of FA in 5 mL THF was prepared. To this mixture, 100 µL of a 1
M solution of DEA in THF was added to the mixture and this allyl deprotection cocktail was
added to the resin. The reaction vessel was sealed and stirred at 500 RPM overnight [56]. The
resin was transferred to a 12 mL Poly-Prep® chromatography column and sequentially washed
with 5 mL of 0.5% DIEA, 5 mL of 0.5% NaDMDTC, 25 mL of DMF, 25 mL of DCM, 25 mL of
DMF, and 25 mL of DCM (Figure 2.3m & Figure 2.4e).
Next, the Fmoc group protecting the terminal Ala was manually removed. (Figure 2.3n &
Figure 2.4f). The free amine of the terminal Ala was cyclized with the free α-carboxyl group of
the allyl-deprotected glutamic acid linker by adding 5 equiv. (250 µmol) of PyBOP, 5 equiv. (250
µmol) of HOBt, and 10 equiv. (500 µmol) of DIEA dissolved in 5 mL of NMP to the rein. The
reaction was allowed to proceed overnight at room temperature on an orbital shaker at 60 RPM.
The resin was filtered using the Poly-Prep® column and washed with 25 mL of DMF and 25 mL
of DCM before being dried under vacuum for 5 minutes (Figure 2.3o & Figure 2.4g). The
completeness of cyclization was determined by the bromophenol blue test.
2.4.2 Inversion and Final Deprotection of the Peptide
In order to invert the peptide, the ester bond between Leu 13 and HMBA was cleaved as
follows. 5 mL of a 1 M aqueous solution of NaOH was added to the resin to hydrolyze the ester
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formed between HMBA and Leu13. The solution was vigorously shaken on a pulsing vortex for 1
hour. The resin was filtered using the Poly-Prep® column and washed with 25 mL of water and
25 mL of DCM and was dried under vacuum (Figure 2.3p & Figure 2.4h).
Lastly, to remove the bioorthoganal protecting groups, 5 mL of a deprotection cocktail
consisting of 84% TFA, 6.5% phenol, 5.0% thioanisole, 2.5% DODT, and 2.0% TIS was added to
the resin and mixed on a pulsing vortex for 90 minutes. The resin was filtered using the PolyPrep® column and washed sequentially with 10 mL of TFA, 10 mL of DCM, 5 mL of DMF, 5
mL of methanol, 5 mL of DCM, 5 mL of DMF, and 5 mL of DMF/water (60/30 v/v) [57]. The
deprotected, inverted peptide library was flushed with nitrogen, sealed, and stored at -20 °C
(Figure 2.3q & Figure 2.4i).

2.5 NTS Controls
A low-surface-density, biphasic NTS control (Figure 2.8a) and a high-surface-density
NTS control (Figure 2.8b) with our native NTS (4-13) binding sequence (Leu13-Tle12-Dmt11Pro10-Arg9-Arg8-Pro7-Lys6-Asn5-Glu4) were each synthesized on 250 mg of TentaGel® S-NH2
resin using methodologies described in sections 2.2.1, 2.2.2, and 2.4. These controls were used to
confirm and optimize cell binding and validate MS/MS analysis and sequence determination
techniques prior to the examination of the experimental peptide library.
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Figure 2.8. NTS controls. (a) Low-surface-density, biphasic, surface-area-reduced, C-terminusdirected exterior native NTS binding sequence (HO2C-Leu13-Tle12-Dmt11-Pro10-Arg9Arg8-Pro7-Lys6-Asn5-Glu4) with high-surface-density N-terminus-directed template
tag for analysis. (b) High-surface-density, C-terminus-directed NTS binding
sequence. (B = ßAla)
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2.6 In Vitro Screening
2.6.1 Cell Culture
The human colorectal adenocarcinoma cell line HT-29 (NCI-PBCF-HTB38) was cultured
under vendor-specified conditions. Cells were subcultured twice weekly in McCoy’s 5A medium
supplemented with 10% FBS, L-glutamine, HEPES, amphotericin B, and Plasmocin™ (Table
2.1) at 37 °C in a humidified incubator containing 5% CO2.
2.6.2 Compound Screening
A 1 mL volume of solid resin was reswollen in 5 mL of water for 30 minutes. The resin
was filtered using the Poly-Prep® column and washed with 15 mL of water and 15 mL of 1x
PBS. The resin was suspended in 5 mL of 1x PBS and thoroughly mixed. 1 mL of the mixed
solution was transferred to a 1.5 mL microcentrifuge tube. The other 4 mL of suspended resin
were set aside.
Cells were grown to about 80% confluency. Used media was removed from the flask and
the flask was washed with 10 mL of 1x PBS. To the flask was added 7 mL of TrypLE™ Express
and incubated at 37 °C for 20 minutes to lift adherent cells. The solution was thoroughly mixed to
ensure the dissociation of all cells from the flask. The solution was transferred to a 15 mL conical
centrifuge tube and centrifuged at 1,500 RPM (RCF = 500) for 5 minutes. The supernatant was
removed, and the pellet was resuspended in 5 mL of PBS. This washing process was conducted
twice. The number of cells present in 20 µL of the resuspended solution was counted using a
hemocytometer. The supernatant was removed, and the washing process was performed one
additional time. The pellet was resuspended in 1 mL of serum-free media (Table 2.2). About 5 x
105 cells were added to each well of a six-well non-culture-treated plate. Enough serum-free
media was added to each well to bring the total volume up to 3 mL. About 2,250 resin beads (~3
µL) were added to each well [58]. The plate was wrapped in foil to protect from the light and
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incubated on a rotary shaker at 60 RPM in a humidified environment containing 5% CO 2 at 37 °C
for 1 hour.
After the incubation period, the cells were observed under a bright-field microscope.
Interactions were categorized qualitatively as negative (Figure 2.9a), positive (Figure 2.9b), or
very positive (Figure 2.9c) [59]. A total of ten positive and very positive hits were selected. Each
resin bead was removed from the cell culture plate individually by pipette to a microscope slide.
Two drops of an acid wash solution containing 50 mM glycine-HCl and 0.1 M NaCl (pH 2.8)
were added to the resin and incubated at room temperature for 5 minutes to dissociate any bound
cells. The resin was washed twice with 1x PBS and transferred to a 96-well plate containing 50
µL of water for cleavage and analysis.
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Table 2.1. HT-29 Cell Culture Media
Reagent

Volume

+ % (v/v)

McCoy’s 5A Medium

500 mL

100

FBS

50 mL

10

L-Glutamine (2 mM)

5 mL

1

HEPES (25 mM)

5 mL

1

Amphotericin B (250

5 mL

1

1 mL

0.2

µg/mL)
Plasmocin™ (25 mg/mL)
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Table 2.2. HT-29 Cell Study Media
Reagent

Volume

+ % (v/v)

McCoy’s 5A Medium

100 mL

100

L-Glutamine (2 mM)

1 mL

1

HEPES (25 mM)

1 mL

1

Amphotericin B (250

1 mL

1

200 µL

0.2

µg/mL)
Plasmocin™ (25 mg/mL)
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Figure 2.9. Cell binding to resin. Cell binding to resin was qualitatively assessed at 100x
magnification under a bright-field microscope. ‘Hits’ were divided into three
categories; (a) negative, (b) positive, & (c) very positive.
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2.7 Sequence Identification
2.7.1 CNBr Cleavage of Compound
CNBr (202 mg) was dissolved in 2 mL of FA. This solution (150 µL) was added to each
well of a 96-well plate containing a resin bead suspended in 50 µL of water to create a cleavage
mixture with a final concentration of 0.5 M CNBr in 70% FA (Figure 2.10). The plate was
wrapped in foil to protect from the light and incubated at room temperature on a rotary shaker at
60 RPM for 4 hours. After the incubation period, the solution from each well was individually
filtered through glass wool-containing pipettes into 5 mL test tubes to separate the resin from the
peptide solution. 1 mL of water was added to each tube and the CNBr solution was allowed to
neutralize in a fume hood for 30 minutes. The pipettes were then washed with 1 mL of a 33/66
(v/v) ACN/Water solution twice to remove any residual peptide and was added to the neutralized
CNBr solution. The peptides were dried overnight in a CentriVap concentrator, capped, and
stored at – 20 °C until analysis.
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Figure 2.10. Cyanogen bromide cleavage. Methionine thioether initiates nucleophilic attack on
CNBr. Methyl thiocyanate is liberated from the compound to form an iminolactone.
The iminolactone is hydrolyzed to cleave the compound from the resin.
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2.7.2 LC-MS/MS and PEAKS® Sequence Identification
Each sample was suspended in 2% ACN and 0.1% FA and loaded onto an Acclaim
PepMap 100 75 µm x 2 cm C-18 LC Columns (Thermo Scientific™) at a flow rate of 4 µL/min
then separated with a Thermo RSLC Ultimate 3000 (Thermo Scientific™) on a Thermo EasySpray PepMap RSLC C18 75 µm x 50 cm C-18 2 µm column (Thermo Scientific™) with a step
gradient of 96-75% solvent A (0.1% FA in water)/4-25% solvent B (0.1% FA in 80% ACN) for
10-57 min and 75%-55% solvent A/25-45% solvent B for 57-62 min at 300 nL/min at 50oC with
a 90 min total run time. Eluted peptides were analyzed by a Thermo Orbitrap Fusion Lumos
Tribrid (Thermo Scientific™) mass spectrometer in a data dependent acquisition mode. A survey
full scan MS (from m/z 350–1800) was acquired in the Orbitrap with a resolution of 120,000. The
AGC target for MS1 was set as 4 × 105 and ion filling time set as 100 ms. The most intense ions
with charge states of 2-6 were isolated in a 3 s cycle and fragmented using HCD fragmentation
with 40 % normalized collision energy and detected at a mass resolution of 30,000 at 200 m/z.
The AGC target for MS/MS was set as 5 × 104 and ion filling time set 60 ms dynamic exclusion
was set for 30 s with a 10-ppm mass window. Example TIC data (RT 70-88 minutes) of Sample 1
is shown in Figure 2.11 denoting the compound of interest at a retention time of 72.65 minutes.
An example of MS1 (precursor ion) and MS2 (precursor ion fragmentation) data at a retention
time of 72.65 minutes for Sample 1 is shown in Figure 2.12 and Figure 2.13 respectively.
Protein identification was performed by searching MS/MS data against a custom database
file containing the sequence: SLLAAEAAENKPRRPYLL (Figure 2.14). The search was set up
for undigested peptides with no specified enzyme. Variable modifications to experimental
residues E, K, and R were set with fixed modifications at S and Y with a maximum of seven
modifications per peptide (Table 2.3). The precursor mass tolerance threshold was set to 12 ppm
and maximum fragment mass error was 0.02 Da. Qualitative analysis was performed using
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PEAKS® 8.5 software. A significance threshold of ≥ 90% of a specific experimental residue (E,
K, or R) detected as modified within a sample was reported.
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Figure 2.11. Sample 1 TIC. Example TIC from Sample 1 at a retention time of 70-88 minutes.
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Figure 2.12. Sample 1 MS1 data. Example of MS1 spectra of Sample 1 at a retention time of
72.65 minutes.
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Figure 2.13. Sample 1 MS2 data. Example MS2 spectra of Sample 1 at a retention time of 72.65
minutes.
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Figure 2.14. PEAKS® custom database input. The PEAKS® software analysis treats unnatural
amino acids as monoisotopic-mass-difference modified versions of natural amino
acids. Thus, unnatural amino acids incorporated in the compound must be designated
as a corresponding natural amino acid and assigned a fixed or variable list of PTMs.
CNBr cleavage converts the Met residue to a homoserine lactone and is assigned as
serine in the database file (Red). ß-Ala residues are assigned as Ala (Orange). Both
the Glu-HMBA linker and experimental position 4 (X4) are assigned as Glu (Green).
Experimental position 3 (X3) is assigned as Lys (Purple). Experimental positions 2
and 1 (X1 & X2) are assigned as Arg (Blue). Dmt is assigned as Tyr (Cyan). Tle is
assigned as Leu (Brown). Residues for which a PTM list are assigned are annotated
with a star of corresponding color – 5 in total: Y, R, K, E, and S.
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Table 2.3. PEAKS® PTM List
Name

Residue Site

Monoisotopic Mass

Type of

Difference (Da)

Modification

Dimethyl Tyrosine

[Y]

+28.031

Fixed

Arg(Me)

[R]

+14.015

Variable

Arg(NO2)

[R]

+44.985

Variable

Cit

[R]

+0.984

Variable

Gln(R Sub)

[R]

-28.043

Variable

Asp(R Sub)

[R]

-41.074

Variable

Lys(Me)

[K]

+14.015

Variable

Lys(Me2)

[K]

+28.031

Variable

Lys(Me3)

[K]

+43.054

Variable

Lys(N3)

[K]

+25.990

Variable

Orn

[K]

-14.016

Variable

Gln(K Sub)

[K]

-0.037

Variable

Asp(K Sub)

[K]

-13.068

Variable

Gln(E Sub)

[E]

-0.984

Variable

Asp(E Sub)

[E]

-14.015

Variable

Glu-HMBA Linker

[E]

+134.037

Variable

Homoserine Lactone

[S]

-3.990

Fixed
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Chapter 3:
RESULTS
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3.1 Synthesis and Screening of Peptide Libraries
In this study, we utilized an OBOC combinatorial peptide library approach to discover
new NTS derivatives with potential for future development as NTSR1-targeted agents. To that
end, we synthesized two inverted, OBOC libraries (Figure 3.1a & b) containing 864 NTS analog
compounds using TentaGel® S-NH2 resin beads. The first library was manually prepared using a
biphasic approach and underwent surface area reduction in order to achieve a low-surface-density
library for the purpose of reducing false positives due to non-specific interactions. A second,
high-surface-density library was prepared using an automated peptide synthesizer for comparison,
forgoing the surface area reduction and biphasic approaches. For both peptide libraries,
substitutions of natural and unnatural amino acids were made at Arg8 (X1), Arg9 (X2), Lys6 (X3)
and Glu4 (X4) with residues presented in Figures 2.4-2.6 in a modified NTS (4-13) binding
sequence (Figure 1.3c). The X1 and X2 positions were varied by the substitution of Arg, Arg(Me),
Arg(NO2), Cit, Gln or Asp. The X3 position was varied by the substitution of Lys, Lys(Me),
Lys(Me2), Lys(Me3), Orn, Gln or Asp. Lastly, the X4 position was varied by the substitution of
Glu, Gln or Asp. Below, we outline the synthesis of these two libraries, their in vitro screening,
and identification of positive hits by MS/MS and PEAKS® Studio software.
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Figure 3.1. Peptide library 1 & 2. (a) Low-Surface-Density Peptide Library. Biphasic, surfacearea-reduced, C-terminus-directed exterior binding sequence with high-density Nterminus-directed template tag for analysis detailed in section 2.2.1. (b) HighSurface-Density Peptide Library. Non-surface-area-reduced, whole-bead, C-terminus
binding sequence detailed in section 2.2.2. (X4 = Glu substitutions, X3 Lys
substitutions, X2 & X1 = Arg substitutions, B = ßAla)
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3.1.1 Low-Surface-Density Peptide Library – Peptide Library 1
Our initial efforts to create this peptide library utilized a surface area reduction procedure
to reduce nonspecific binding interactions during the screening process and a biphasic approach
to include an N-terminus-directed template tag to accommodate analysis by PED-MALDI (Figure
3.1a). Initial surface area reduction was carried out to 80% by incubation in water overnight and
exposure to a mixture of Boc-Phe-OSu and Fmoc-Met-OSu in DCM/diethyl ether to selectively
couple exterior amines (Figure 2.1). Anchors bound with Boc-Phe were deprotected and capped
through the addition of excess acetic anhydride to terminate the growing peptide. The Fmoc-Met
served both as the starting point for the synthesis of the C-terminus-directed peptide as well as the
cleavage point to remove the final compound from the resin. Fmoc-Met was then conjugated to
the remainder of free interior amines in the biphasic system (Figure 2.2a) to serve as the interior
cleavage point to remove the final compound from the resin and a starting point for the synthesis
of the N-terminus-directed growing peptide. This surface area reduction step was later abandoned
in the synthesis of the High-Surface Density Peptide Library due to cell screening issues that
arose and will be addressed later in this section. Similarly, the biphasic approach was abandoned
after establishing that PED-MALDI was not needed for peptide identification.
Next, a small peptide linker composed of Leu, Leu, ß-Ala, and ß-Ala was conjugated to
the growing interior and exterior peptides using standard Fmoc-HATU chemistry. The two Leu
residues were initially added to increase the mass of the peptides in order to make them easily
distinguishable from matrix material during PED-MALDI analysis whereas the two ß-Ala
residues were introduced to further space the binding sequence from the resin matrix. Though our
intention to analyze the compounds by PED-MALDI was later abandoned, this primary linker
was conserved across both peptide libraries to increase the distance between the resin and the
targeting vector thereby helping to reduce sterics and ensure adequate binding. The resin was
swollen in water overnight and exposed to Fmoc-Glu-OAll in DCM/diethyl ether to selectively
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couple it to the exterior amines of the biphasic system. This group served as the anchor point for
the future cyclization and inversion of the completed exterior peptide as generally described in
section 1.2. Subsequently, HMBA was coupled to Glu-OAll and was the starting point for the
synthesis of the exterior NTS binding sequence. Lastly, Gly and Ala were conjugated to the
interior region of the resin to maintain similar interior and exterior peptide lengths.
Subsequently, the first amino acid of the binding sequence (Leu 13) was conjugated to the
interior Ala using standard Fmoc-HATU chemistry and to the exterior HMBA using Steglich
esterification. A mixture of Fmoc-Leu-OH, DIC, and DMAP in DCM was added to the resin and
incubated overnight to conjugate Leu13 to the primary alcohol of HMBA. The ester formed
between Leu13 and HMBA served as a point for future inversion of the exterior binding sequence
through hydrolysis of that bond after cyclization to yield the C-terminus-directed sequence.
Subsequent amino acids (Tle12-Dmt11-Pro10-X1-X2-Pro7-X3-Asn5-X4) were sequentially
conjugated to the growing peptide of both the interior and exterior sequences using standard
Fmoc-HATU chemistry with a split-mix procedure employed at the Arg9 (X1), Arg8 (X2), Lys6
(X3) and Glu4 (X4) positions to substitute in experimental modifications (Figure 2.5-2.7). Finally,
a terminal linker consisting of two Ala residues was conjugated to the resin. The purpose of this
linker was to increase the distance of the inverted binding sequence from the primary linker to
reduce its influence on binding of the compound.
In order to cyclize the exterior binding sequence, the allyl protecting group was then
removed from Glu-OAll by overnight treatment with a mixture containing Pd(PPh3)4, TPP, FA,
and DEA in THF. Next, the Fmoc was removed from the terminal Ala residue and the resin was
treated with a mixture containing PyBOP, HOBt, and DIEA in NMP overnight to cyclize the free
amine of Ala with the free α-carboxyl group of the allyl-deprotected glutamic acid linker. The
resin was then treated with NaOH to hydrolyze the ester formed between HMBA and Leu13 to
yield the inverted, C-terminus-directed binding sequence for cell-binding analysis. Finally, the
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bioorthogonal protecting groups were removed by treatment with a standard deprotection
cocktail.
Early analysis of our low-surface-density NTS control compound (Figure 2.8a) by MS
failed to identify the expected single or multi-charged parent ion. Instead, many smaller
fragments related to the control sequence were observed. Initially, this observation was attributed
to the failed cyclization of the peptide. If the allyl group protecting the α-carboxyl of the GluHMBA linker was not removed as intended, attempts to cyclize and hydrolyze the peptide would
cause the NTS binding and terminal regions to be cleaved from the resin. This would result in
only the primary linker being resin-bound (Figure 3.2). To further examine this reaction, a
sequence containing only the primary linker (Met-Leu-Leu-[ß-Ala]-[ß-Ala]-[Glu-OAll]-HMBA)
was synthesized. The allyl group was initially removed by overnight treatment with a solution
containing 1 equiv. of Pd(PPh3)4, 3 equiv. of TPP, and 10 equiv. of FA/DEA in THF. After allyl
deprotection of 25 mg of resin containing the linker sequence and MS analysis, the expected
allyl-deprotected parent ion was observed in low abundance. Various reaction conditions were
tested [23,56,64,65] using 25 mg aliquots of the same resin to optimize the allyl deprotection
reaction by increasing the yield of the allyl-deprotected parent ion. The highest parent ion yield
was observed when conditions reported by Corey and Reichard were used, detailed in section
2.4.1 that included the overnight treatment of the resin with 0.05 equiv. Pd(PPh3)4, 0.10 equiv. of
TPP, and 1 M FA/DEA in THF [56]. However, upon treatment of the NTS control compound
under these ideal reaction conditions for the allyl deprotection followed by analysis by MS, the
expected parent ion was again not observed. This suggested that the allyl deprotection was not
the primary issue. Further investigation found this issue was due to unexpected fragmentation
during CNBr cleavage. A more detailed description of this problem and how it was resolved is
further addressed in section 3.2.
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Figure 3.2. Failed allyl deprotection. If the allyl deprotection step were to fail, no carboxyl group
would be present to form a peptide bond between the Glu-HMBA linker and the free
amine of the terminal alanine. Cyclization would fail. Subsequent hydrolysis of the
ester bond formed between HMBA and Leu13 would result in breakage of the
sequence. Washing would elute the free binding/terminal linker sequence leaving
only the primary linker attached to the resin for removal and analysis. (B = ßAla)
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To validate our screening approach, cell screening was carried out with our low-density
NTS control peptide using NTSR1+ HT-29 cells according to the methodology detailed in section
2.6. Unfortunately, very low cell binding was observed during these preliminary experiments. It
has been reported this surface area reduction methodology can sometimes complicate the
screening process as the amount of compound carried by a single bead may be insufficient for hit
identification [62]. This prompted us to pursue the synthesis of high-density peptide libraries
(Figure 2.8b) without surface area reduction. Using the high-density NTS control peptide, cell
binding was found to be significantly improved. As a consequence, the Low-Surface-Density
Peptide Library was never screened and the surface area reduction for the peptide libraries was
abandoned.
3.1.2 High-Surface-Density Peptide Library – Peptide Library 2
The second peptide library we synthesized (High-Surface-Density Peptide Library) did
not include the surface area reduction step or the biphasic approach (Figure 3.1b). The surface
area reduction was abandoned after determination the low surface density was interfering with
cell binding during initial in vitro screening. The biphasic approach was also abandoned in the
synthesis of this library as we intended to instead analyze the compounds by de novo peptide
sequencing through MS/MS, therefore eliminating the need to include an N-terminus-directed
template tag. The detailed synthesis of our High-Surface-Density Peptide Library is described in
section 2.2.2 and was carried out based on the rationale described in the previous section.
Following the completed synthesis, the High-Surface-Density Peptide Library was
screened in vitro against NTSR1+, HT-29 cells grown and maintained to vendor’s standards.
Initially, about 5 x 105 cells in serum-free media were transferred to each well of a non-culturetreated plate. Serum-free media was used in order to eliminate the possibility of serum proteins
interacting with the resin and producing false negative results [58]. A non-culture-treated plate
was used to facilitate the free movement of the resin within the well to increase the incidence of
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interactions between the cells and the resin as typical culture-treated (Lys-coated) well plates
have been reported to anchor the resin to the bottom of the plate and significantly reduce cellresin interactions [58]. Next, roughly 2,250 resin beads were added to each well and incubated for
1 hour. After the incubation period, the plates were observed under a bright-field microscope and
hits were categorized as shown in Figure 2.9. A total of 10 positive hits (6 very positive and 4
positive) were selected at random from a large pool of positive beads in addition to 1 control
(very positive) for identification.

3.2 Sequence Identification
3.2.1 CNBr Cleavage of Compound
Initial CNBr cleavage of the peptide from the resin was carried out overnight in the dark
with an excess of CNBr in 70% TFA [23,61]. The CNBr cleavage reaction is highly effective at
fragmenting Met residues resulting in the released peptide with a terminal homoserine lactone.
However, it was later determined that these conditions were also leading to unexpected
fragmentation of the peptide observed in the MS spectra which we had originally attributed to
incomplete allyl deprotection. After establishing that the initial conditions of the CNBr cleavage
were at fault, the cleavage reaction was carried out under milder conditions, namely a CNBr
solution in 70% FA for 4 hours. This methodology resulted in obtaining the intact peptide with
much lower amounts of observable fragmentation. The explanation as to why the CNBr reaction
carried out in 70% TFA for overnight resulted in reproducible fragmentation of the peptide while
70% FA for 4 h did not is not clear. Due to the scope of this project, further investigation of this
unexpected fragmentation was not pursued. While obtaining the intact peptide was important to
validate our synthetic approach, it should be noted that this observed fragmentation is not
necessarily an impediment to sequence identification since fragmentation would be a
consequence of sequence analysis.
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3.2.2 LC-MS/MS and PEAKS® Sequence Identification
After CNBr cleavage, the compounds were analyzed by LC-MS/MS and PEAKS®
Studio software for sequence identification using the methodology detailed in section 2.7.2. Of
the 10 experimental samples, 2 samples were lost during the post-cell study washing and CNBr
cleavage steps. These samples were lost as a result of the difficulty associated with manually
isolating, transferring, and washing the positive hits for analysis. Of the remaining 8 experimental
samples, 5 were classified as very positive (++) (Figure 2.8a) and 3 were classified as positive (+)
(Figure 2.8b). The control sample was classified as very positive (++).
The PEAKS® software de novo analysis of the MS/MS spectra detects and establishes
the sequence of a peptide from the masses of complementary y and b ion fragments (Figure 3.3).
The determined peptide fragment sequence(s) (shown as # of peptides) in each sample are
aggregated and queried against a database to establish coverage of a full-length peptide (Figure
3.4). PEAKS® overall peptide analysis of the samples is presented in Table 3.1 where -10logP is
the PEAKS® peptide score; the score indicates significance of a peptide-precursor spectrum
match with a quarried database (-10logP ≥ 13 is equivalent to a p-value ≤ 0.05) [80]. PEAKS®
analysis determined our NTS sequence was present in every sample with statistical significance
and fragment coverage of 100% of our experimental NTS(4-13) sequence. Modifications detected
by PEAKS® analysis of each sample is reported in Table 3.2 where -10logP represents the
significance of the peptide-precursor spectrum match with the quarried database of the specific
peptide(s) where the modification was found. The modification -10logP value for the control are
not present as no experimental modifications were detected (Table 3.10).
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Figure 3.3. PEAKS® de novo peptide view. Example of PEAKS® spectrum annotation from a
peptide detected in Sample 1 (AAeAAENk). Y fragments ‘k’ and ‘NEAAeAA’ (red)
with complementary b fragment AAeAAENk (blue). (e = HMBA Linker, k =
Lys(Me2))
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Figure 3.4. PEAKS® protein view. Example of PEAKS® peptide coverage from sample 2.
Analysis detected five overlapping peptide sequences for 100% coverage of the
queried database sequence.
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Table 3.1. PEAKS® Overall Peptide Analysis
Sample

-10logP

Coverage %

# of Peptides

Screening

p value

Classification
1

52.49

100

26

++

5.64E-06

2

52.25

100

5

++

5.96E-06

3

123.39

100

12

++

1.15E-13

4

44.79

100

5

++

3.30E-05

5

44.16

100

2

++

3.80E-05

6

46.42

100

4

+

2.30E-05

7

143.12

100

7

+

4.88E-15

8

44.76

89

2

+

3.30E-05

Control

26.71

100

2

++

2.13E-03
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Table 3.2. PEAKS® Peptide Analysis of Samples
Sample

Target

Detected

%

%

Residue

Experimental

Modified

Unmodified

-10logP

p value

Modifications
1 (++)

Lys6

Lys(Me2)

98.45

1.55

21.94

6.40E-03

2 (++)

Glu4

Gln

100

0

15.23

3.00E-.02

Lys6

Lys(Me2)

91.94

8.06

15.23

3.00E-.02

3 (++)

Arg9

Arg(NO2)

96.04

3.96

18.54

1.40E-02

4 (++)

Glu4

Gln

100

0

20.73

8.45E-03

Arg9

Arg(NO2)

100

0

20.73

8.45E-03

5 (++)

Lys6

Lys(Me2)

100

0

33.25

4.73E-04

6 (+)

Lys6

Lys(Me)

91.92

8.08

19.12

1.22E-02

Arg8

Gln

100

0

23.11

4.89E-03

Arg9

Gln

100

0

23.11

4.89E-03

7 (+)

Glu4

Gln

100

0

78.64

1.37E-08

8 (+)

Glu4

Gln

95.02

4.98

36.37

2.31E-04

Control

-

-

0

100

-

-
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Analysis of samples 1-8 showed the modification sites with the most favorable
observed binding affinity toward NTSR1 to be Glu4 (X4) and Lys6 (X3), with 50% (4) of the
samples showing modifications at those positions. The modification site with the second most
favorable observed binding affinity toward NTSR1 was Arg9 (X1), with 38% (3) of the samples
showing modifications at that residue. The modification site with the least favorable observed
binding affinity toward NTSR1 was Arg8 (X2), with only 13% (1) of the samples registering a
modification at that residue (Figure 3.5). The modification breakdown for each residue is shown
in Table 3.3. The most favorable observed binding affinity toward NTSR1 was exhibited by the
modification of Gln in place of Glu 4 (X4), which was observed in all 4 samples with modifications
at that residue. The modification with the second most favorable observed binding affinity toward
NTSR1 was Lys(Me2) in place of Lys 6 (X3), which was observed in 3 of the 4 samples with
modifications at that residue with the other modification being Lys(Me). The modification with
the third most favorable observed binding affinity toward NTSR1 was Arg(NO 2) in place of Arg9
(X1), which was observed in 2 of the 3 samples with modifications at that residue with the other
modification being Gln. The modification with the least favorable observed binding affinity
toward NTSR1 appeared to be Gln in place of Arg8 (X2), present in only 1 of 8 samples. Based on
this limited data, NTS (4-13) sequences with combinations of modifications which afford
favorable observed binding affinity to NTSR1 (Gln in place Glu 4, Lys(Me2) in place of Lys6, and
Arg(NO2) in place of Arg9) should be selected and resynthesized for further in vitro and in vivo
validation and investigation.
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Total Modifications by Residue
(Samples 1-8)

Experimental Residue

Modified

38%

R9

R8

Unmodified

62%

13%

87%

K6

50%

50%

E4

50%

50%
% of Total Samples

Figure 3.5. Total Modifications by Residue (Samples 1-8). E4 and K6 were the most commonly
modified residues, detected in 50% of total samples followed by R 9 modified in 38%
of total samples and R8 modified in 13% of total samples.
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Table 3.3. Modification Breakdown by Residue
Target Residue

Total Number of Detected

Modification Breakdown

Experimental Modifications
Glu4

4

4 = Gln

Lys6

4

3 = Lys(Me2)
1 = Lys(Me)

Arg8

1

1 = Gln

Arg9

3

2 = Arg(NO2)
1 = Gln
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Chapter 4:
DISCUSSION
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For this project we examined the use of an OBOC peptide library approach to discover
new NTS derivatives with potential for future development as NTSR1-target agents. Our overall
objective is to find modified NTS sequences with increased, or at least retained, NTSR1 binding
affinity, increased metabolic stability, and decreased renal uptake. To this end, we synthesized
two inverted, OBOC peptide libraries (Figure 3.1a & b) containing 864 NTS analogs using
TentaGel® S-NH2 resin beads. The choice of TentaGel® S-NH2 resins is common for the
synthesis of inverted OBOC libraries [23,57,59,60-63,68]. The TentaGel® S-NH2 resin lacks the
standard cleavable groups, such as acid-labile moieties, present with other common solid-phase
peptide synthesis resins. Instead, a Met residue is inserted into the peptide and serves as a
cleavage point under treatment with CNBr. The lower 0.25 mmol / g loading TentaGel® S-NH2
resin is favored for use in this OBOC peptide library application over the higher 0.45 mmol / g
loading resin to reduce the possibility of non-specific interactions that may arise in screening very
high-density libraries [23,60-63].
The first attempt at the OBOC approach was to synthesize the Low-Surface-Density
Peptide Library. This library was manually prepared using biphasic segregation and underwent
surface area reduction. The biphasic approach was originally pursued in order to generate an Nterminus-directed template sequence for analysis by Edman sequencing [23]. The resulting
peptide ladder would be analyzed by PED-MALDI and from this the sequence could be
determined [13]. The purpose of the surface area reduction was to reduce false positives due to
non-specific interactions during in vitro screening. However, it was determined that the surface
area reduction interfered with compound screening by significantly reducing cell binding. As a
consequence, a second, High-Surface-Density Peptide Library was prepared using automated
solid-phase peptide synthesis, forgoing the surface area reduction. In addition, the biphasic
approach for peptide identification was also abandoned in preference of de novo sequencing by
MS/MS. It was decided that de novo sequence identification would be a simpler analysis
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technique compared to PED-MALDI analysis. In addition, de novo sequencing by MS/MS would
not require biphasic segregation making the generation of the library more straight-forward.
The first step in the synthesis of the library was incorporation of the primary linker
sequence. The primary linker includes the Met residue that will eventually be utilized to cleave
the peptide from the resin. It also includes residues that can facilitate MS/MS analysis and
lengthen the peptide chain to reduce steric hindrance and enhance ligand-cell binding interactions
upon screening. For our peptide libraries, the primary linker Met-Leu-Leu-[ß-Ala]-[ß-Ala] was
utilized. This particular sequence was based on work by Kunys, Lian, and Pei [61].
The lack of plasma stability due to rapid degradation has been a major hurdle to
overcome in the design of imaging and therapeutic agents based on NTS. The rapid degradation
of NTS results in metabolites with little to no NTR1 affinity leading to poor in vivo tumor uptake
[69-72]. To stabilize NTSR1-targeted agents from degradation, a major focus has been placed on
modifying the essential NTS(8-13) sequence to increase metabolic stability. N-methyl
modification at Arg8 is a common stabilizing modification but was not included in this work
because Arg8 was a target of our experimental substitutions. Two other common modifications to
the NTS(8-13) sequence are the introduction of alternative amino acid residues at the Tyr 11 and
Ile12 positions [73-78]. The substitution of Dmt in place of Tyr 11 has been shown to significantly
increase metabolic stability of NTS at little cost to binding affinity [77]. Moreover, the
substitution of Tle in place of Ile12 is considered one of the most important stability-increasing
modifications to NTSR1-targeted agents. This modification has been shown to greatly increase in
vitro (4.3% to 72% present in human serum after 24-hour incubation) and in vivo (0.8% to 10.0%
intact peptide in plasma after 15 minutes) stability but also results in a significant decrease to
binding affinity (6.7 ± 0.3 nM to 41.2 ± 6.2 nM) [76,79].
Both NTS peptide libraries (NTS(4-13) sequence = Glu(X4)-Asn-Lys(X3)-Pro-Arg(X2)Arg(X1)-Pro-Dmt-Tle-Leu) underwent split-mix substitutions of charged amino acid residues by
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natural and unnatural amino acids at Arg8 (X1), Arg9 (X2), Lys6 (X3) and Glu4 (X4). The variable
residues at these positions are outlined in Figures 2.4-2.6. Structurally similar derivatives of the
natural amino acids were used in an effort to maintain native receptor-ligand interactions since
substantial modifications have been shown to negatively impact binding affinity [81]. As
previously described, the introduction of unnatural amino acids has been demonstrated to greatly
increase the stability of NTS and other peptides. This was a major consideration in the selection
of experimental residues for substitution. Additionally, the charge of the substituted amino acid
relative to the native amino acid was another very important consideration for the selection of
experimental residues for substitution. The translation of radiotherapeutic peptides, such as
NTSR1-targeted agents, into the clinic has been hampered by high renal uptake related to the
increasing molecular (positive) charge of the peptides which can result in dose-limiting toxicities
[85, 90]. A variety of reports have investigated both the mechanism and structure-activity
relationships corresponding to the renal uptake and retention of radiolabeled peptides [85-87].
These reports have found the renal reuptake of cationic peptides is generally facilitated by
interactions with the negatively charged brush border of the proximal tubular cells and receptormediated endocytosis by megalin and cubilin receptors [85]. Ultimately, the experimental
residues chosen for substitution were designed to afford the best chance at discovering an NTSR1
targeting vector with comparable affinity to NTSR1, acceptable in vivo stability, and tolerable
kidney retention.
After cyclization, inversion, and final deprotection, the High-Surface-Density Peptide
Library was screened in vitro against NTSR1+ HT-29 cells. A total of 10 experimental samples
(6 very positive and 4 positive) and 1 control sample (very positive) as shown in Figure 2.9 were
selected at random from a large pool of positive hits for identification. During the screening
process and isolation of the positive hits, 2 samples were lost. The samples were lost as a result of
the difficulty associated with manually isolating, washing, and transferring the individual hits.
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The methodology described herein is very low-throughput and leaves a large margin for humanassociated error. Standard OBOC library screening is generally conducted using a COPAS Plus
automated bead sorter from Union Biometrica [91-93]. The COPAS Plus bead sorter allows for
accurate high-throughput screening, fluorescence quantification, and sorting of cell-associated
hits in applications where the diameter of the cell-associated resin beads is too large for analysis
with FACS [92]. This would have been ideal for use in this application but, unfortunately, our lab
does not have access to this instrumentation.
Next, the identified hits were processed for sequence analysis. The unknown peptides
were removed from the resin beads by treatment with a 0.5 M CNBr solution in 70% FA for 4
hours. These optimal cleavage conditions were discovered after initial problems occurred with
excessive peptide fragmentation with exposure to 70% TFA overnight. Multiple groups have
reported the use of a weaker acid such as FA as an alternative to TFA [60,66-68] for sensitive
applications. Through trial and error of the various cleavage conditions described by these
groups, the conditions affording the minimal amount of fragmentation was determined to be
treatment with the 0.5 M CNBr solution in 70% FA for 4 hours. As previously stated, we are not
certain why the CNBr reaction carried out in 70% TFA for an extended period of time resulted in
reproducible fragmentation of the peptide. This phenomenon was not further investigated due to
the scope of this research. This excessive fragmentation hindered initial efforts to confirm our
synthetic approach through analysis of an intact peptide by LC-MS. However, this would not
have been an impediment to ultimate analysis by LC-MS/MS as fragmentation of the peptide is
facilitated during de novo sequencing.
A total of 8 experimental samples (5 very positive and 3 positive) and 1 control sample
(very positive) were analyzed by LC-MS/MS and PEAKS® Studio (Table 3.1 & Table 3.2).
Though PEAKS® analysis only reported coverage for sample 8 at 89%, the reported
experimental modification results are still significant as the NTS(4-13) experimental region
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retained 100% coverage. The modification with the most favorable observed binding affinity
toward NTSR1 was Gln in place of Glu4 which was observed in all 4 samples with modifications
at that residue (Figure 3.5 & Table 3.3). Glu4 is not normally included in NTS analogs as it is
relatively far from the binding sequence and is regularly reported to have little to no impact on
the binding affinity of the NTS. This was demonstrated in a 2015 experiment conducted by Lee et
al. in which NTS analogs with a neutral (Ala) and a positive (Lys) substitution at Glu 4 exhibited
similar EC50 values (0.6 ± 0.1 nM and 1.4 ± 0.1 nM) to the 0.8 ± 1.0 nM value of the native NTS
sequence [89]. Since one of the primary interests of this research was related to the overall charge
of the peptide, it was appropriate for us to include Glu4 despite the minimal role that position
plays in NTS binding [89].
The replacement of Lys(Me2) in place of the Lys6 in 3 samples afforded the second most
common modification found in the analyzed NTSR1-binding hits. To date, NTSR1-targeted
radiopharmaceuticals have been largely based on two targeting vector constructs: NTS (6-13) and
NTS (8-13). While the NTS (8-13) sequence contains all of the necessary interactions to ensure
low nanomolar binding affinity to NTSR1, the NTS (6-13) fragment Lys6 site offers a convenient
functionalization site outside of the binding pocket for the incorporation of chelation systems
[83]. The inclusion of the Lys 6 residue to the native NTSR1 targeting vector has been shown to
marginally increase binding affinity over the NTS (8-13) sequence [84]. However, the inclusion
of an unmodified Lys6 residue to the sequence adds another positive charge to the peptide and is
shown to significantly increase renal retention [85-87]. The Lys(Me2) modification in place of
Lys6 is likely to show no significant change in the binding affinity of NTS to NTSR1 compared to
the non-modified NTS (6-13) sequence.
The third most common modification found from the strong NTSR1-binding hits was
Arg(NO2) in place of Arg9, which was found in 2 samples. The importance of conserving the
positive charge of the Arg8 and Arg9 residues for high NTSR1-binding affinity is well
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documented [30]. The positively charged arginine side chains of the ligand interact with the
electronegative rim of the binding pocket. Modifications made to the Arg8 and Arg9 positions
which alter this charge interaction with the receptor have thus far been reported to universally
reduced binding affinity [81]. Interestingly, the Arg9 residue is reported to be more critical in
binding to NTSR1 than the Arg8 residue. Various modifications made to Arg8 and Arg9 in
research conducted by Lundquist et al. in 2008 concluded the Arg8 position can tolerate an array
of modifications while still retaining comparable NTSR1 binding affinity whereas the Arg 9 is not
as amenable to changes without significantly reducing binding affinity [81]. This phenomenon
was later corroborated by Dzimbova and Pajpanova in 2017 [82]. The Arg(NO2) modification in
place of Arg9 is likely to increase plasma stability of NTS while reducing binding affinity to
NTSR1 [81]. This modification may also be of interest in addressing the kidney uptake and
retention issues of NTSR1-targeted agents. The replacement of the positively charged Arg 9
residue with the neutral Arg(NO2) group would reduce the overall charge of NTS and possibly
help reduce renal retention of the compound while still exhibiting favorable binding affinity
toward NTSR1 [86].
Sample 6 exhibited weak binding affinity for NTSR1 and was determined to have
modifications of the substitution of Gln for both Arg8 and Arg9. These modifications were not
detected in any other sample. As previously discussed, the conservation of charge in the Arg8 and
Arg9 residues is important in maintaining high binding affinity toward NTSR1 [30]. While a
charge-reducing modification to one Arg residue has been demonstrated to reduce the relative
potency of binding to NTSR1 by nearly 50%, removing the charge from both Arg residues
simultaneously has been shown to almost completely destroy the binding profile of NTS (90%
reduction in relative potency of binding) [81]. The replacement of both positively charged Arg
residues with a neutral amino acid such as Gln would significantly alter the NTS interaction with
the NTSR1 binding pocket and likely exhibit very low binding affinity toward NTSR1. The
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potential for these modifications to effect binding affinity was corroborated by our screening
classification of sample 6 as weakly binding (Figure 2.9b). For this reason, the Arg modifications
present in sample 6 would likely not be further pursued.
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Chapter 5:
CONCLUSION
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5.1 Summary
An OBOC combinatorial peptide library approach was used to discover new NTS
derivatives with potential for future development as NTSR1-targeted agents. To that end, we
synthesized two inverted, OBOC libraries containing 864 NTS analog compounds using
TentaGel® S-NH2 resin beads. The first Low-Surface-Density Peptide Library was manually
prepared using a biphasic approach for analysis by partial Edman’s sequencing/PED-MALDI and
underwent surface area reduction to achieve a low-surface-density library to reduce false
positives due to non-specific interactions. After screening issues related to the surface area
reduction of low-surface-density library arose, a second, High-Surface-Density Peptide Library
was prepared using an automated peptide synthesizer for analysis by MS/MS, forgoing the
surface area reduction and biphasic approaches. For both peptide libraries, substitutions of natural
and unnatural amino acids were made at Arg8 (X1), Arg9 (X2), Lys6 (X3) and Glu4 (X4) in a
modified NTS (4-13) binding sequence. The High-Surface-Density Peptide Library was screened
in vitro against NTSR1+ HT-29 cells and 8 positive hits were identified, isolated, and analyzed
by LC-MS/MS and PEAKS® Studio software. The modifications with the most favorable
observed binding affinity toward NTSR1 were Gln at Glu4 (X4), Lys(Me2) at Lys6 (X3), and
Arg(NO2) at Arg9 (X1).
Many issues in the optimization of synthesis and screening arose throughout this project.
As our lab does not have any previous experience with peptide library or combinatorial chemistry
techniques, most of these issues had to be addressed through the referencing of literature and a
series of trial-and-error. Though not the initial intention, a great deal of the time spent on this
project was devoted to solving these issues and developing a standard operating procedure
framework for synthesis and screening of OBOC libraries for future use in our lab. The results
obtained, and methodologies established from this research serve as a starting point for further
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validation and optimization of NTS or other peptide targeting sequences for our lab using onebead one-compound combinatorial chemistry techniques.

5.2 Future Directions
It is important to note that the modifications to each residue may have a certain effect
alone which differs from the effect of an NTS sequence with multiple modifications. Therefore, it
is necessary to further explore combinations of these identified modifications and other stabilityincreasing modifications for their effect on the binding affinity to NTSR1, metabolic stability,
and renal retention. The future direction of this research should consist of further validation of
identified hits and subsequent screening of these validated hits for stability and renal retention
properties. Sequences containing all possible combinations of modifications with the most
favorable observed binding (Gln for Glu4, Lys(Me2) for Lys6, and Arg(NO2) for Arg9) and
regularly used stability-increasing modifications (Dmt 11, and Tle12) should be resynthesized,
rescreened, and reanalyzed to validate our findings. Validated hit sequences should then be
resynthesized to perform an in vitro internalization assay with HT-29 cells against the native NTS
sequence. Hits with significantly better or comparable internalization characteristics to the NTS
control should be further evaluated in vitro for renal uptake characteristics. Ultimately, in vivo
studies for tumor uptake, stability, and renal retention properties should be performed.
Discussion during the defense of this thesis brought about a few more issues for future
improvements to this methodology. A comparison between post-cell-study MS and pre-cell-study
MS data of compounds should be made to identify the extent of cellular contaminants in the postcell study spectra. If such contaminants are identified, more robust washing methods should be
pursued as well as screening the compounds against a more diverse database of peptides to
identify possible background proteins. Additionally, the overall distribution of modifications
present in a heterogeneous sample of resin should be checked to ensure equal representation of
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the modifications. Both of these techniques would help generate more robust, higher quality MS
data to better support experimental conclusions.
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